NT 10-K: Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT
Published on April 30, 2009
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
|
(Check
One):
|
x Form
10-K
|
o Form
20-F
|
o Form
11-K
|
o Form
10-Q
|
|
o Form
N-SAR
|
o Form
N-CSR
|
|
For
Period Ended: January
31, 2009
|
|
|
o Transition Report
on Form 10-K
|
|
|
o Transition Report
on Form 20-F
|
|
|
o Transition Report
on Form 11-K
|
|
|
o Transition Report
on Form 10-Q
|
|
|
o Transition Report
on Form N-SAR
|
|
| For the Transition Period Ended: |
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
Nothing
in this form shall be construed to imply that the Commission
has
verified any information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
APOLLO MEDICAL HOLDINGS,
INC.
Full name
of Registrant
N/A
Former
Name if Applicable
1010 N. Central
Avenue
Address
of Principal Executive Office (Street and
Number)
Glendale, CA
91202
City,
State and Zip Code
PART
II - RULE 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or
expense;
|
|
| x |
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form
10-Q, or portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
|
PART
III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR,
N-CSR, or the transition report portion thereof could not be filed within the
prescribed time period.
(Attach
extra sheets if needed.)
The
compilation, dissemination and review of the information required to be
presented in the Form 10-K for the relevant period has imposed time constraints
that have rendered timely filing of the Form 10-K impracticable without undue
hardship and expense to the registrant. The registrant undertakes the
responsibility to file such report no later than fifteen days after its original
prescribed due date.
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
A.
Noel DeWinter
|
(818)
|
507-4617
|
|
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been
filed? If the answer is no, identify
report(s). Yes x No o
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? Yes o No x
|
If so:
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if
appropriate,
state the reasons why a reasonable estimate of the results cannot be
made.
APOLLO MEDICAL HOLDINGS,
INC.
(Name of
Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date: April
30, 2009
|
By:
|
/s/ A. Noel DeWinter | |
|
A.
Noel DeWinter
Chief
Financial Officer
|
|||
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be filed with the form.